Lekha Mikkilineni

129 posts

Lekha Mikkilineni

Lekha Mikkilineni

@LMikkMD

Assistant Professor in the BMT Division at Stanford University School of Medicine . I focus on multiple myeloma and CAR T-cell therapy.

Palo Alto, CA Se unió Temmuz 2018
864 Siguiendo505 Seguidores
Lekha Mikkilineni retuiteado
Peter Forsberg MD
Peter Forsberg MD@ForsbergMD·
Our data from @ColoradoBlood is out now. We developed an approach using dex for excessive lymphocyte expansion after Cilta-Cel. Instituted along with more stringent bridging we subsequently observed improvements in non-relapse mortality and reduced severe atypical neurotox events
Robert Z. Orlowski@Myeloma_Doc

#Myeloma Paper of the Day: Dexamethasone prophylaxis for high lymphocyte expansion (ALC >5000/μL, which predicted severe early neurologic events/high mortality) post-cilta-cel in myeloma demonstrates promise for risk mitigation, including better OS: pubmed.ncbi.nlm.nih.gov/41894686/. #mmsm

English
2
3
29
4.2K
Lekha Mikkilineni retuiteado
John Gubatan MD
John Gubatan MD@JGubatanMD·
Thank you @MayoClinic for featuring our study. @JHashashMD @ibdgijami @FarrayeIBD @VKumbhari @mikewallacemd @MayoClinicFLGIH
Mayo Clinic@MayoClinic

Vitamin D supplementation may help shape how the immune system responds to gut bacteria in people with inflammatory bowel disease (IBD), according to a Mayo Clinic–led study published in Cell Reports Medicine. The findings offer new insight into how the immune system and gut microbiome interact in this chronic condition and point to potential new therapeutic strategies. Learn more: mayocl.in/4bPByLE

English
0
2
13
742
Lekha Mikkilineni retuiteado
Andrew Portuguese, MD
Andrew Portuguese, MD@AJPortuguese·
📄1/ Our multicenter real-world study of elranatamab in relapsed/refractory multiple myeloma is out today in @BloodCancerJnl. The main finding: outcomes in routine practice were meaningfully less favorable than those reported in MagnetisMM-3 cohort A. nature.com/articles/s4140…
English
4
10
39
3.5K
Lekha Mikkilineni retuiteado
Saurabh Zanwar
Saurabh Zanwar@ZanwarSaurabh·
Congratulations @MattReesMD! More evidence to support the use of CAR-T in appropriately selected patients with MM/AL
Rahul Banerjee, MD, FACP@RahulBanerjeeMD

🙏🏽 @AjHematology: 🇺🇸 Myeloma Immunotherapy Consortium analysis of CAR-T in AL amyloidosis n=28 (n=6 with ❤️ 3A dz at infusion). Yes CRS, yes IEC-HS (rare), but no TRM... And yes very deep responses 🤩 Some day this may be default answer for fixing outcomes gap if ≤hemVGPR

English
0
4
15
2.5K
Lekha Mikkilineni retuiteado
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
🙏🏽 @AjHematology: 🇺🇸 Myeloma Immunotherapy Consortium analysis of CAR-T in AL amyloidosis n=28 (n=6 with ❤️ 3A dz at infusion). Yes CRS, yes IEC-HS (rare), but no TRM... And yes very deep responses 🤩 Some day this may be default answer for fixing outcomes gap if ≤hemVGPR
Rahul Banerjee, MD, FACP tweet media
English
1
10
43
9K
Lekha Mikkilineni retuiteado
Andrew Portuguese, MD
Andrew Portuguese, MD@AJPortuguese·
Measles is back. For myeloma patients after ASCT, MMR often gets delayed because of vaccine timing & concern about dara maintenance. This multicenter study provides reassuring safety data & should give clinicians confidence to vaccinate when appropriate. ashpublications.org/bloodneoplasia…
Rahul Banerjee, MD, FACP@RahulBanerjeeMD

Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time. "Can I get MMR 💉 on dara-len maintenance?" Short answer: 💯%, it seems! Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!

English
0
4
15
1.7K
Lekha Mikkilineni retuiteado
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
Excellent @BloodPortfolio work by @HitomiHosoyaMD @LMikkMD at Al! How enteric lymphomas (rarely) form after cilta-cel CAR-T. (Photo from accompanying commentary by @MarcelaMaus) 1️⃣ can’t identify unless you look for clone 2️⃣ overlapping spectrum with IEC-EC 3️⃣ CsA can work!
Rahul Banerjee, MD, FACP tweet media
Lekha Mikkilineni@LMikkMD

Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine - out in @BloodPortfolio. doi.org/10.1182/blood.…

English
0
4
24
3K
Lekha Mikkilineni retuiteado
Adam Rodman
Adam Rodman@AdamRodmanMD·
Our study of AMIE at @BIDMC_Medicine is out! You can read about what we did in posts from my co-authors (including the Google post below). But I wanted to talk about some background for this study, and what I think are most interesting findings. 🧵⬇️ x.com/GoogleResearch…
Google Research@GoogleResearch

Today we announce results from a first-of-its-kind study with @BIDMC_Medicine on AMIE, our conversational AI for clinical reasoning. In a real-world clinical study, AMIE was found to be safe, feasible, and well-received by patients. Learn more: goo.gle/4sXCogz

English
5
28
99
57.7K
Lekha Mikkilineni retuiteado
Anmol Goyal
Anmol Goyal@AnmolGoyalMD·
Shoutout to our CHIP team and especially my mentor @CloneTracker for his guidance on our work looking at longitudinal clonal evolution/stability in cancer survivors! Grateful to @AACR for the award and opportunity to share our findings. @CCF_IMCHIEFS
Anmol Goyal tweet media
English
1
4
38
2.2K
Lekha Mikkilineni retuiteado
Hamza Hashmi
Hamza Hashmi@hhashmi87·
Hepta-refractory='New' End-Stage #MultipleMyeloma @RascheLeo nature.com/articles/s4137… ➡️Resistance to CD38 abs + 2 IMiDs + 2 PIs + BCMA & GPRC5D Rx ➡️37 pts → median OS 12.8m, very short PFS (<3m) ➡️WGS (17 pts): 41% biallelic BCMA loss, 35% GPRC5D loss, 29% BOTH ➡️Branching evolution=multiple independent clones with different antigen-loss events emerge within the same pt ➡️Antigen escape drives end-stage resistance → test (combine WGS+IHC) before retreat! #MMSM #Unmetneed
Hamza Hashmi tweet mediaHamza Hashmi tweet mediaHamza Hashmi tweet media
English
2
10
25
2.7K

Descubrir

@BloodCancerJnl @thisisJamesD @khouri_jack @ForsbergMD @AimazAfrough @ldandersonjr @leshune @TomBmt133